The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides

IFN-α with its cytotoxic effects on tumorous T cells was introduced in the treatment of cutaneous T-cell lymphoma in the 1980s and is included as an option in CTCL guidelines. (1) However, recombinant IFN a-2a or IFN a-2b interferon regimens are no longer available and therefore, the pegylated analogue (pegylated IFN a-2a, Pegasys; Hoffmann-La Roche) has been currently used. Nevertheless, treatment outcomes have only been reported in case reports and in a few clinical trials.(2)(3)(4) The current study aimed to evaluate the efficacy and safety profile of peg IFN in the treatment of mycosis fungoides (MF).